Anti-RSV Study in Chinese Patients (ASCENT)

NCT03699202 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: AK0529
DRUG: Placebo

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.